While there is a subset of patients who are appropriately treated with RT alone, increasingly, combined modality therapy has been used in patients with locally advanced HNC. The role of chemotherapy in addition to cetuximab and RT remain unclear, and future studies will need to examine the interplay of RT, chemotherapy, and targeted therapies such as cetuximab.